Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Inogen, Inc. (NASDAQ:INGN - Free Report) by 312.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 174,625 shares of the medical technology company's stock after purchasing an additional 132,287 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.74% of Inogen worth $1,694,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in shares of Inogen during the 2nd quarter valued at $30,000. CWM LLC increased its holdings in Inogen by 2,185.9% during the 2nd quarter. CWM LLC now owns 6,629 shares of the medical technology company's stock worth $54,000 after purchasing an additional 6,339 shares during the last quarter. XTX Topco Ltd acquired a new stake in Inogen in the second quarter valued at $178,000. Price T Rowe Associates Inc. MD raised its stake in shares of Inogen by 5.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,868 shares of the medical technology company's stock valued at $193,000 after purchasing an additional 1,188 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC lifted its holdings in Inogen by 153.1% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 25,393 shares of the medical technology company's stock worth $206,000 after buying an additional 15,361 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company's stock.
Inogen Trading Down 1.8 %
Shares of Inogen stock traded down $0.18 on Tuesday, reaching $9.60. 155,070 shares of the company were exchanged, compared to its average volume of 330,145. The firm has a market capitalization of $228.65 million, a price-to-earnings ratio of -4.28 and a beta of 1.04. Inogen, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $13.33. The stock has a fifty day moving average price of $9.60 and a 200-day moving average price of $9.63.
Analyst Ratings Changes
INGN has been the subject of a number of analyst reports. StockNews.com lowered Inogen from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a report on Friday, November 8th.
View Our Latest Report on INGN
Inogen Profile
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Articles
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
